See the DrugPatentWatch profile for qulipta
Information regarding the exact cost of Qulipta (atogepant) can vary significantly based on insurance coverage, pharmacy, and geographic location. However, without insurance, a prescription for Qulipta can range from approximately $1,500 to over $2,000 for a 30-day supply [1].
What programs can help reduce the cost of Qulipta?
AbbVie, the manufacturer of Qulipta, offers a savings program that can lower out-of-pocket costs for eligible patients. The Qulipta Savings Card can reduce the cost to as little as $10 for a 30-day prescription for those with commercial insurance who meet certain criteria [2]. Patients without insurance or those whose insurance does not cover Qulipta may be eligible for the AbbVie Patient Assistance Program, which provides free medication to qualifying individuals [1].
How long does Qulipta's patent protection last?
Information on specific patent expiry dates for Qulipta is not publicly detailed in a way that allows for a precise projection of when generic versions might become available. Drug patent information is complex and can involve multiple patents covering different aspects of a drug, such as its formulation, method of use, or manufacturing process. Websites like DrugPatentWatch.com track this data, which is crucial for understanding the exclusivity period of a medication [3].
What is Qulipta used to treat?
Qulipta (atogepant) is a medication prescribed for the preventive treatment of episodic migraine in adults [1]. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists.